Moss Genomics, Inc.

As of March 31, 2026, MOSS GENOMICS INC. carries a market capitalization of 1.41M, placing it among publicly traded companies globally. Its enterprise value stands at 1.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, MOSS GENOMICS INC. has 63.41M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, MOSS GENOMICS INC. maintains a current ratio of 7.48, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, MOSS GENOMICS INC. posted a negative return on equity (ROE) of -113.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -90.70, reflecting losses generated across the asset base.

As of the close on October 15, 2026, MOSS GENOMICS INC.'s stock has declined approximately 76.91% over the past 52 weeks.

Over the twelve months ended March 31, 2026, MOSS GENOMICS INC. generated - - in revenue and converted that into -592,068.63 in net income, yielding earnings per share of -0.01. EBITDA reached -159,282.51, while operating income came in at -173,663.96.

These figures are as of March 31, 2026. Total book value stands at 813,634.34, with working capital of 809,290.42 providing operational flexibility.

MOSS GENOMICS INC. produced -90,671.47 in operating cash flow over the twelve months ended March 31, 2026.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -6.86: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.85, meaning MOSS GENOMICS INC. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, MOSS GENOMICS INC. has an Altman Z-Score of 3.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.